Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring

L.G. van Vlerken, F.I. Lieveld, S. van Meer, G.H. Koek, K.M. van Nieuwkerk, P. Friederich, J.E. Arends, P.D. Siersema, D.M. Burger, K.J. van Erpecum

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND AND OBJECTIVE: Adherence is essential in antiviral therapy for chronic hepatitis C. We investigated the effect of real-time medication monitoring on adherence to ribavirin. METHODS: In this randomized controlled trial, patients in the intervention group received a medication dispenser that monitored ribavirin intake real-time during 24 weeks PEG-interferon/ribavirin+/-boceprevir or telaprevir. Patients in the control group received standard-of-care. Adherence was also measured by pill count. RESULTS: Seventy-two patients were assigned to either intervention (n=35) or control groups (n=37). Median adherence by pill count was 96% (range: 43%-100%) with 30 (94%) of patients exhibiting>/=80% adherence. Perfect adherence (i.e. 100%) was similar in intervention and control groups: 22 (85%) vs. 15 (75%) (P=0.47). Adherences by real-time medication monitoring and by pill count did not correlate (R=0.19, P=0.36). No predictors of poor adherence could be identified. Ribavirin trough levels after 8 weeks (median: 2.4 vs. 2.7mg/L, P=0.30) and 24 weeks (median: 3.0 vs. 3.0mg/L, P=0.69), and virological responses did not differ between intervention and control groups. CONCLUSIONS: Adherence to ribavirin during PEG-interferon containing therapy in chronic hepatitis C is high. Real-time medication monitoring did not influence adherence to ribavirin, plasma ribavirin levels or virological responses.
Original languageEnglish
Pages (from-to)622-630
Number of pages9
JournalClinics and research in hepatology and gastroenterology
Volume40
Issue number5
DOIs
Publication statusPublished - Nov 2016

Keywords

  • SUSTAINED VIROLOGICAL RESPONSE
  • VIRUS-INFECTION
  • THERAPEUTIC STRATEGIES
  • PLUS RIBAVIRIN
  • BOCEPREVIR
  • TELAPREVIR
  • INHIBITORS
  • PLASMA
  • IMPACT

Cite this